Allergan's Trivaris approved to treat retinal diseases

Article

Allergan, Trivaris, retinal diseases, vision loss, ocular

Trivaris (triamcinolone acetonide injectable suspension) 80 mg/mL is a new anti-inflammatory drug from Allergan to treat retinal diseases that can result in vision loss. A synthetic glucocorticoid corticosteroid, the product is an intravitreal shot that treats sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. The Irvine, Calif., firm said the introduction marks its first product for back-of-the-eye diseases.

To see more Daily News articles, click here.

To go to the Drug Topics homepage, click here.

Newsletter

Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.

Recent Videos
Related Content
© 2025 MJH Life Sciences

All rights reserved.